-
公开(公告)号：US20200024319A1
公开(公告)日：2020-01-23
申请号：US15565376
申请日：2016-05-04
Applicant: AMGEN INC. , Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Ai Ching LIM , Randal Robert KETCHUM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20210139554A1
公开(公告)日：2021-05-13
申请号：US17065395
申请日：2020-10-07
Applicant: Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20140286898A1
公开(公告)日：2014-09-25
申请号：US14209699
申请日：2014-03-13
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Gunasekaran KANNAN , Li LI , Joshua T. PEARSON , Margaret KAROW
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20240327486A1
公开(公告)日：2024-10-03
申请号：US18627761
申请日：2024-04-05
Applicant: Amgen Inc.
Inventor： Eric Alan BUTZ , Christy Ann THOMSON , Marc Alain GAVIN , Ian Nevin FOLTZ , Dong XIA , Dina N. ALCORN , Randal Robert KETCHEM , Ai Ching LIM , Kathy MANCHULENKO , Laura SEKIROV , Kelly Ann BERRY , Cyr Clovis Chua DE IMUS , Neeraj Jagdish AGRAWAL , Gunasekaran KANNAN , Li LI
CPC classification number: C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US20230139534A1
公开(公告)日：2023-05-04
申请号：US18068970
申请日：2022-12-20
Applicant: AMGEN INC.
Inventor： Marc A. GAVIN , Li LI
IPC: C07K14/55
Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
-
Patent Agency Ranking
公开(公告)号：US20210094997A1
公开(公告)日：2021-04-01
申请号：US17063566
申请日：2020-10-05
Applicant: Amgen Inc.
Inventor： Marc Alain GAVIN , Gunasekaran KANNAN , Li LI , Joshua Thomas PEARSON , Margaret KAROW
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20170313753A1
公开(公告)日：2017-11-02
申请号：US15649520
申请日：2017-07-13
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Li LI
Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
-
公开(公告)号：US20140343252A1
公开(公告)日：2014-11-20
申请号：US14209914
申请日：2014-03-13
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Gunasekaran KANNAN , Li LI , Joshua T. PEARSON , Margaret KAROW
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
Abstract translation: 本文提供了IL-2突变蛋白和IL-2突变蛋白Fc-融合分子，其优先扩增和激活T调节细胞并且适于大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 此外，本文提供了当在哺乳动物细胞中表达时被糖基化的接头肽。
-
9.发明申请公开(公告)号：US20130195795A1
公开(公告)日：2013-08-01
申请号：US13672417
申请日：2012-11-08
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Li LI
IPC: C07K14/55
Abstract: Described herein are immunosuppressive molecules including immunosuppressive variants of IL-2, and use of such molecules to treat inflammatory and autoimmune disorders.
Abstract translation: 本文描述的是免疫抑制分子，包括IL-2的免疫抑制性变体，以及这些分子用于治疗炎性和自身免疫性疾病。
-
公开(公告)号：US20170137485A1
公开(公告)日：2017-05-18
申请号：US15408281
申请日：2017-01-17
Applicant: Amgen Inc.
Inventor： Marc A. GAVIN , Gunasekaran KANNAN , Li LI , Joshua T. PEARSON , Margaret KAROW
IPC: C07K14/55
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.018 seconds)
